Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates

Nektar Therapeutics (NKTR) incurred an adjusted loss per share of 18 cents in first-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 21 cents.The adjusted loss excluded the impact of restructuring costs. After including restructuring costs, the loss was 19 cents per share compared with a loss of 73 cents in the year-ago quarter.Total revenues were almost flat year over year at $21.6 million in the first quarter. Revenues beat the Zacks Consensus Estimate of$15 million.Quarter ...